1. Generics Bulletin
  2. >>Products

Complex Generics Drought Could Make Teva Stock ‘Relatively Rudderless’

Israeli Firm Aiming For Gx Forteo, Xulane To Cross The Line In 2023

 
• By Dean Rudge

The market has responded to Teva’s newly released 2023 financial guidance, with lingering questions over its ability to hit its forecasts amid a continued dearth of complex generics and further investments in Teva’s pipeline.

2005-built capesize dry bulker Baltimore formerly Diana Shipping
• Source: Shutterstock

Teva’s share price dipped nearly 10% after it published its year-end financial results and guidance for 2023 last week, leaving the market to pick the bones out of the company’s base business and planned strategic update, set to be revealed midyear by new company CEO Richard Francis.

Former Biogen and Sandoz exec Francis told investors during the company’s 8 February earnings call that Teva hopes 2023 may...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Pipeline And Parent: Meitheal CEO Shea Talks Paclitaxel And What’s Next

 
• By Dean Rudge

In an exclusive interview, Meitheal Pharmaceuticals CEO Tom Shea discusses the company’s oncology strategy following the recent launch of generic Abraxane, alongside discussion of complex injectables, the biosimilars pipeline, and how $300m in backing is fueling the company's next phase of growth.

Endo Offloads Paladin As Shareholders Approve Mallinckrodt Merger

 
• By Dave Wallace

As it prepares to complete its $6.7bn merger with Mallinckrodt, Endo has divested its International Pharmaceuticals business – consisting primarily of Canadian specialty firm Paladin Pharma – to Knight Therapeutics.

Canada Joins Global Push To Drop Costly Clinical Trials For Biosimilars

 
• By Neena Brizmohun

Health Canada’s proposal to no longer require biosimilar manufacturers to prove the safety and efficacy of their product through Phase III clinical trials marks a pivotal change in Canada’s regulatory approach.